Patent EP0455482A2 successfully refreshed from Google Patents.
EP0455482A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
A subset of human progenitor cells
Assignee: Becton Dickinson and Co
•
Filing: 1991-05-01
•
Granted: —
•
Expires: 2011-05-01
Abstract
Abstract A substantially pure population of human progenitor stem cells which lack CD38 but express CD34 is claimed. These stem cells are pluripotent and are capable of blast colony formation. These cells may be used in bone marrow transplantation and gene therapy.
Inventors
- 👤 Leon Terstappen
- 👤 Michael Loken
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 14:23
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0634; C12N5/0636; C12N5/0647; A61K48/00
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
29 words
A substantially pure population of human cells comprising pluripotent hematopoietic stem cells that express the CD34 antigen but lack expression of the CD38 antigen and other lineage associated antigens.
Claim 2
Dependent Claim
14 words
The population of claim 1 wherein the cells are derived from a hematopoietic tissue.
Claim 3
Dependent Claim
14 words
The population of cells of Claim 2 wherein the cells are derived from marrow.
Claim 4
Dependent Claim
14 words
The population of cells of claim 3 wherein the cells are derived from blood.
Claim 5
Independent Claim
29 words
A method for isolating a substantially pure population of human cells comprising pluripotent hematopoietic stem cells wherein hematopoietic cells are selected on the basis of CD34 and CD38 expression.
Claim 6
Dependent Claim
25 words
The method of claim 5 wherein the stem cells are labelled with one or more labelled monoclonal antibodies that react differentially with CD34 and CD38.
Claim 7
Dependent Claim
27 words
The method of claim 5 or 6 wherein the method for selection includes means capable of discriminating between cells that react differentially with fluorescently labelled monoclonal antibodies.
Claim 8
Dependent Claim
12 words
The method of claim 7 wherein said means comprises a flow cytometer.
Claim 9
Independent Claim
68 words
A method for altering the genome of a population of hematopoietic stem cells that express the CD34 antigen but lack expression of other lineage associated antigens to insert a gene capable of producing a functional gene product comprising the steps of: a) obtaining the gene coding for the gene product from a source; and b) inserting the gene into one or more of the cells in the population.
Claim 10
Dependent Claim
19 words
The method of claim 9 wherein the gene isolated is inserted into a vector capable of transfecting the cells.
Claim 11
Dependent Claim
11 words
The method of Claim 10 wherein the vector is a retrovirus.
Claim 12
Dependent Claim
20 words
The method of claim 9 wherein the source of the gene is DNA isolated from cells of a normal donor.
Claim 13
Dependent Claim
20 words
A substantially pure population of human stem cells comprising a population of cells that are uncommitted to any specific lineage.
Claim 14
Dependent Claim
17 words
A substantially pure population of human stem cells comprising a population of self-renewing blast colony forming cells.
Claim 15
Dependent Claim
16 words
The population of claim 14 wherein the cells are CD34⁺/CD38⁻ and lack other lineage associated antigens.
Claim 16
Dependent Claim
32 words
The method of claim 5 wherein the cells are isolated by sequential passage of cells through one or more solid support means to which one or more monoclonal antibodies are affixed thereto.
Claim 17
Dependent Claim
19 words
The method of claim 16 wherein one of said antibodies affixed to said means is an anti-CD34 monoclonal antibody.
Claim 18
Dependent Claim
19 words
The method of claim 16 wherein one of said antibodies affixed to said means is an anti-CD38 monoclonal antibody.
Claim 19
Dependent Claim
27 words
The method of claim 16 wherein said antibodies affixed to one of said means comprises monoclonal antibodies against CD38 and one or more other lineage associated antigens.
Claim 20
Dependent Claim
19 words
The population of claim 1, 13 or 14 wherein the cells are exposed to one or more growth factors.
Claim 21
Dependent Claim
11 words
The population of claim 20 wherein the growth factor is GM-CSF.
Claim 22
Dependent Claim
12 words
The method of claim 6 wherein the label is a fluorescent marker.
Claim 23
Dependent Claim
16 words
The method of claim 6 wherein the label comprises a magnetic bead and a fluoresent marker.
Claim 24
Dependent Claim
17 words
The method of claim 16 wherein one or more of the antibodies are conjugated to a label.
Claim 25
Dependent Claim
14 words
The method of claim 6 or 24 wherein the label is a magnetic bead.
Claim 26
Dependent Claim
13 words
The method of claim 16 wherein the support means comprises a magnetic bead.
Claim 27
Dependent Claim
15 words
The method of claim 26 wherein the magnetic bead is labelled with an anti-mouse immunoglobulin.
Claim 28
Dependent Claim
34 words
The method of claim 16 wherein cells are passed first through a support means having affixed thereto anti-CD34 monoclonal antibodies and then are passed through a support means having affixed thereto anti-CD38 monoclonal antibodies.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.